CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: August-03-12
Credit Expiration Date: August-03-13


David S. Boyer, MD
Retina-Vitreous Associates Medical Group
Beverly Hills, CA

Peter K. Kaiser, MD
Professor of Ophthalmology
Chaney Family Chair for Ophthalmology Research
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Cleveland, OH

Michael Ip, MD
Associate Professor
Department of Ophthalmology and Visual Sciences, University of Wisconsin
Co-Director, Fundus Photograph Reading Center
Madison, WI

Credit Hours



Mobile + Online on RealCME

Program Description

Age-related macular degeneration (AMD) is a disorder of the macula and a leading cause of visual impairment in developed countries. The prevalence, incidence, and progression of AMD increase with age and it accounts for almost half of the cases of severe visual loss (visual acuity of 20/200 or worse) in people older than 40 years of age in the United States. In the past decade, pharmacologic therapies have become available that allow the maintenance and even improvement of vision in patients with neovascular AMD, for whom previously the visual prognosis was poor.

Considerable uncertainty exists among ophthalmologists and other clinicians involved in the management of patients with AMD about how best to employ pharmacologic options to provide the greatest efficacy and safety while at the same time minimizing the burden of treatment.

The goal of this continuing education activity is to improve the ability of ophthalmologists to treat and manage their patients with neovascular AMD, maximizing efficacy and safety while minimizing the burden on the patients and the health care system.

Program Developer/Facilitator


Target Audience

This activity is designed for ophthalmologists and other specialists who care for patients with AMD.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Better utilize current therapies for individual patients with AMD.
  2. Identify the roles of new and emerging therapies in the treatment of AMD.
  3. Better utilize monitoring techniques to assess response to therapy in patients with AMD.
  4. Incorporate strategies to adjust individualized treatment protocols to optimize patient response to therapy in AMD.


Dr. Boyer discloses that he has served on the advisory boards of Alcon, Allergan, Inc., Genentech, GlaxoSmithKline, Regeneron, Allegro Ophthalmics, and Novartis. He has also served as a consultant for Alcon, Allergan, Genentech, and Regeneron. He has served on the speakers' bureaus of Allergan and Genentech.

Dr. Kaiser discloses that he has served on the advisory board of Bausch and Lomb. He has also served as a consultant for Alcon, Regeneron, Bayer, Novartis, Genentech, and Kanghong.

Dr. Ip discloses that he has served as a consultant for Allergan, Regeneron, and Genentech.

Rick Ricer, MD, physician reviewer, has no conflicts of interest to disclose.

Susan P. Tyler, MEd, CCMEP, FACEHP, has no conflicts of interest to disclose.

Tim Donald, MCM Education medical writer, has no conflicts of interest to disclose.

Kathleen Hines, MCM Education associate editorial director, has no conflicts of interest to disclose.

Credit Statements

This activity has been planned and implemented in accordance with the Essentials Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Cincinnati and MCM Education. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this Enduring Material Activity for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

A review committee has agreed that this material can be completed in 45 minutes. This estimated study time in turn has determined the credit hours being offered.

There are no fees for participating in and receiving CME credit for this online educational activity. By reviewing the course content and successfully completing the post-test and evaluation, clinicians are entitled to receive credit. The statement of credit will be available to print from your user history page.
Read the learning objectives and faculty disclosures
Participate in the activity
Complete the post-test and activity evaluation
Clinicians who successfully complete the post-test and evaluation will receive a CME certificate; successful completion is defined as a cumulative score of at least 80% correct
All other participants who successfully complete the post-test and evaluation will receive a certificate of participation

Commercial Support Statements

This activity is supported by an educational grant from Genentech Immunology and Ophthalmology.

Certificate Fee



The opinions or views expressed in this CME activity are those of the presenters and do not necessarily reflect the opinions or recommendations of the University of Cincinnati, MCM Education, or the commercial supporter(s). Participants should critically appraise the information presented and are encouraged to consult appropriate resources for information surrounding any product, device, or procedure mentioned.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu